. The difference remained significant if the analysis was restricted to patients presenting with ulcer complications. Four patients with ulcer recurrence (14%) were taking NSAIDs at the time of re-presentation compared with 6.6% of survivors at the time of examination of general practitioner records. This difference did not reach significance (x2=1.07). Only one of these four patients was receiving concurrent antiulcer treatment. Overall only one of 75 patients who used NSAIDs during the follow up period died of an ulcer complication (1.3%), a patient taking low dose aspirin who suffered a recurrent ulcer bleed, compared with 1.8% of those not using the drugs.
Patient questionnaire When patients themselves were asked about their health 132 of 158 previous NSAID users admitted to suffering locomotor symptoms at some time during the follow up period (84%) compared with 65 of 100 previous non-users (65%) (X2=1066, p<0O01, Table IV ). This was consistent with the data on general practitioner consultations for locomotor symptoms, although patients reported a higher level of symptoms than recorded by their general practitioners.
In 52 (33%) of the 158 previous NSAID users arthritic pain was such that it was reported to interfere with daily activities compared with 15 (15%) of the 100 previous nonusers (x2=9.31, p<0.01). Of the previous NSAID users 62% said they took regular analgesia of some form for locomotor symptoms compared with 37% of previous non-users (X2=14.39, p<0-001). This use was largely among previous uses of non-aspirin NSAIDs -85 of 103 (82%) compared with 13 of 55 (24%) who were receiving aspirin at initial presentation (X2=50.32, p<0.001).
Patients were also asked whether their subsequent analgesic treatment controlled their symptoms adequately. Only 28% (18%) of the respondents who previously used NSAIDs and reported subsequent locomotor symptoms felt that their subsequent (largely non-NSAID) treatment provided pain relief all the time and 50 (38%) felt pain was not ever controlled adequately with the drug treatment they were given. Among the smaller number of previous non-users with arthritic symptoms the proportions were similar. Thus, overall 32% of all Misoprostol was available during the period of our study, but its use was too low to comment on any value. A number of patients were taking low dose aspirin. This treatment is now recognised to be associated with an increased risk of ulcer bleeding, but use will probably increase further.16 Eradication of Helicobacter pylori is increasingly pivotal in the treatment of non-NSAID patients, including those who present with ulcer bleeding.17 18Although our study was a survey of treatment practice rather than one randomised controlled trial, our results suggest that a further change in treatment, for NSAID patients, would be worth evaluating. We have shown on the one hand that stopping NSAIDs in this group is associated with a high prevalence of locomotor symptoms and on the other hand that further use of NSAIDs (usually in the context of coadministration of an antiulcer drug) is not associated with a catastrophic level of ulcer complications. A controlled comparison of the effects of NSAID cessation or NSAID continuation with concurrent prophylaxis on morbidity and quality of life would seem to be wortiwhile. 
